An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A

An Exploratory Psoriasis Plaque Test Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A as Tool Compound

The purpose of this study is to evaluate the anti-psoriatic effect of injected Botulinum toxin type A compared to that of injected vehicle.

Inclusion Criteria:

• Age 18 years or above
• A diagnosis of psoriasis vulgaris with lesions located on arms and/or legs and/or trunk
• Chronic stable psoriasis vulgaris diagnosed more than 6 months prior to screening.
• Women must use a reliable contraceptive during the trial.

Exclusion Criteria:

• Pregnant or breast feeding women, or women planning to become pregnant.
• Skin infection at injection sites
• Use of biological therapies or small molecules (marketed or not marketed) with a possible effect on psoriasis vulgaris
• Use of systemic treatments with a potential effect on psoriasis vulgaris
• Exposure to phototherapy within 4 weeks for PUVA and 2 weeks for UVB prior to Randomisation
• Use of potent or very potent (WHO group III-IV) corticosteroids for topical treatment of psoriasis within a 4 week period prior to randomisation
• Use of muscle relaxants
• History of dysphagia or aspiration
• Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis